| Indication |
Phase |
Sample Size |
Study
Design/Services |
| Healthy Subjects (Rheumatoid Arthritis) |
1 |
60 |
Double-blind,
placebo-controlled, randomized, multiple ascending dose study |
| Healthy Subjects (Rheumatoid Arthritis) |
1 |
70 |
Single ascending dose,
double-blind, placebo-controlled, randomized study |
| Lipohypertrophy (HIV) |
3 & 4 |
2500 |
A long-term observational safety study |
| Osteoarthritis |
3 |
250 |
Multi-center, open-label
extension study |
| Osteoarthritis |
3 |
300 |
Multi-center,
randomized, double-blind, placebo-controlled study |
| Osteoarthritis of the Knee |
2a |
92 |
Multi-center, randomized, double-blind, placebo-controlled study |
| RA, MS, Atherosclerosis, and Scleroderma |
N/A |
N/A |
Revised an Investigator Brochure |
| Rheumatoid Arthritis |
2 |
100 |
Multi-center,
double-blind, parallel group, randomized, placebo-controlled
study |
